Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS
- 364 Downloads
Post-marketing drug surveillance is largely based on signals found in spontaneous reports from patients and healthcare providers. Rare adverse drug reactions and adverse events (AEs) that may develop after long-term exposure to a drug or from drug interactions may be missed. The US FDA and others have proposed that web-based data could be mined as a resource to detect latent signals associated with adverse drug reactions.
Recently, a web-based search query method called a query log reaction score (QLRS) was developed to detect whether AEs associated with certain drugs could be found from search engine query data. In this study, we compare the performance of two other algorithms, the proportional query ratio (PQR) and the proportional query rate ratio (Q-PRR) against that of two reference signal-detection algorithms (SDAs) commonly used with the FDA AE Reporting System (FAERS) database.
In summary, the web query methods have moderate sensitivity (80%) in detecting signals in web query data compared with reference SDAs in FAERS when the web query data are filtered, but the query metrics generate many false-positives and have low specificity compared with reference SDAs in FAERS.
Future research is needed to find better refinements of query data and/or the metrics to improve the specificity of these web query log algorithms.
- 4.Morel P, Vandel B. Adverse drug reaction monitoring and the Internet: evaluation of the use of the Internet by French Pharmacovigilance Centres and a non-exhaustive survey of websites of interest for collecting information about adverse drug reaction. Therapie. 1999;54(5):525–32.PubMedGoogle Scholar
- 9.Dal Pan G, editor. Adverse event reporting and medication safety considerations: a view from CDER’s Office of Surveillance and Epidemiology. CHPA Regulatory, Scientific, and Quality Conference: Washington, DC; 2013.Google Scholar
- 10.US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for industry. Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines. Rockville: US Department of Health and Human Services; 2001.Google Scholar
- 11.Odgers DJ, Harpaz R, Callahan A, Stiglic G, Shah NH. Analyzing search behavior of healthcare professionals for drug safety surveillance. Pac Symp Biocomput. 2015:306–17.Google Scholar